18 results on '"Ishigooka, Jun"'
Search Results
2. From Perospirone and Blonanserin to Lurasidone
3. Several supplementary concepts for applied category-theoretical states over an extended Petri net using an example relating to genetic coding: Toward an abstract algebraic formulation of molecular/genetic biology
4. A rare genetic variant in the cleavage site of prepro-orexin is associated with idiopathic hypersomnia
5. Randomized open-label study of second-generation antipsychotics for the treatment of schizophrenia: 104-week final results of the JUMPs study assessing treatment discontinuation, remission, and social functioning.
6. Effect of intermittent subchronic MK‐801 administration on dopamine synthesis capacity and responsiveness in the prefrontal cortex
7. Feasibility of remote interviews in assessing disease severity in patients with major depressive disorder: A pilot study
8. Lurasidone in the long-term treatment of Japanese patients with bipolar I disorder: a 52 week open label study
9. Effects of chronic haloperidol treatment on the expression of fear memory and fear memory extinction in the cued fear‐conditioned rats.
10. Efficacy and Safety of Blonanserin Oral Tablet in Adolescents with Schizophrenia : A 6-Week, Randomized Placebo-Controlled Study
11. Efficacy and Safety of Blonanserin Oral Tablet in Adolescents with Schizophrenia : A 6-Week, Randomized Placebo-Controlled Study
12. Long-Term Safety and Efficacy of Blonanserin Oral Tablet in Adolescents with Schizophrenia: A 52-Week, Multicenter, Open-Label Extension Study
13. Efficacy and Safety of Blonanserin Oral Tablet in Adolescents with Schizophrenia: A 6-Week, Randomized Placebo-Controlled Study
14. Corrigendum to “Lurasidone in the Long-Term Treatment of Bipolar I Depression: A 28-week Open Label Extension Study”. [Journal of Affective Disorders 281 (2021) 160–167]
15. Discontinuation and remission rates and social functioning in patients with schizophrenia receiving second‐generation antipsychotics: 52‐week evaluation of JUMPs, a randomized, open‐label study
16. 32.7 Long-Term Safety and Efficacy of Blonanserin Oral Tablet (DSP-5423) in Adolescents With Schizophrenia: A 52-Week, Multicenter, Open-Label, Extension Study
17. Discontinuation and remission rates and social functioning in patients with schizophrenia receiving second‐generation antipsychotics: 52‐week evaluation of JUMPs, a randomized, open‐label study.
18. Association between TNF-α & IL-6 level changes and remission from depression with duloxetine treatment.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.